ERK1/ERK2 and associated pathways have been reported to be modulated by TRPM8 expression in bone cancer (Wang et al., 2013), bladder cancer (Wang et al., 2020), pancreatic cancer (Yee et al., 2012a) and glioblastoma (Alptekin et al., 2015). This evidence concerns the gene TRPM8 and familial pancreatic carcinoma.